173 related articles for article (PubMed ID: 7998111)
21. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
Chatenoud L
Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
[No Abstract] [Full Text] [Related]
22. CD3-specific antibodies: a portal to the treatment of autoimmunity.
Chatenoud L; Bluestone JA
Nat Rev Immunol; 2007 Aug; 7(8):622-32. PubMed ID: 17641665
[TBL] [Abstract][Full Text] [Related]
23. CD3 antigen modulation in T-lymphocytes during OKT3 treatment.
Magnussen K; Klug B; Møller B
Transplant Proc; 1994 Jun; 26(3):1731. PubMed ID: 8030108
[No Abstract] [Full Text] [Related]
24. Preventing the rejection of grafted human fetal pancreas.
Tuch BE; Beretov J; Mackie JD; Beynon S; Simpson AM; Rolph M
Transplant Proc; 1994 Apr; 26(2):704. PubMed ID: 8171616
[No Abstract] [Full Text] [Related]
25. Clinical development of Orthoclone OKT3.
Cosimi AB
Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
[No Abstract] [Full Text] [Related]
26. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
Sasaki AW; Lee RG; Porayko MK; Benner KG; Hennell KR; Wheeler LJ; Pinson CW
Transplantation; 1993 Jan; 55(1):216-9. PubMed ID: 8420054
[No Abstract] [Full Text] [Related]
27. CD3-specific antibody-induced active tolerance: from bench to bedside.
Chatenoud L
Nat Rev Immunol; 2003 Feb; 3(2):123-32. PubMed ID: 12563296
[TBL] [Abstract][Full Text] [Related]
28. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD2 monoclonal antibodies synergize with anti-CD3 to prolong allograft survival and decrease cytokine production.
Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
Transplant Proc; 1993 Feb; 25(1 Pt 1):823-4. PubMed ID: 8094913
[No Abstract] [Full Text] [Related]
30. Forty years of publication of transplantation proceedings-the third decade: the expansion of the enterprise.
Kahan BD
Transplant Proc; 2009 Dec; 41(10):3975-4020. PubMed ID: 20005335
[No Abstract] [Full Text] [Related]
31. Immunology. Policing the immune system.
Wickelgren I
Science; 2004 Oct; 306(5696):596-9. PubMed ID: 15498987
[No Abstract] [Full Text] [Related]
32. Low-dose anti-CD3 therapy provides long-term graft survival in a Lewis rat to C57BL/6 xeno-islet transplantation model.
Jeyarajah DR; Schmeisser FS; Josephson MA; Sohn DG; Thistlethwaite JR
Transplant Proc; 1994 Apr; 26(2):771-3. PubMed ID: 8171656
[No Abstract] [Full Text] [Related]
33. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
Wang XH; Xie T
Chin Med J (Engl); 1993 Nov; 106(11):821-4. PubMed ID: 8143493
[TBL] [Abstract][Full Text] [Related]
34. Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study.
Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
Hum Antibodies; 1997; 8(2):95-8. PubMed ID: 9289394
[TBL] [Abstract][Full Text] [Related]
35. Counting of lymphocyte subpopulations using standard versus low-dose antiCD3 monoclonal antibody treatment.
González-Martínez F; Curi L; Núñez H; González AC; Orihuela N; González G; Orihuela S
Transplant Proc; 2004; 36(6):1659-60. PubMed ID: 15350443
[TBL] [Abstract][Full Text] [Related]
36. Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.
Belmar NA; Lombardo JR; Chao DT; Li O; Ma X; Pong-Afar M; Law DA; Starling GC
J Neuroimmunol; 2009 Jul; 212(1-2):65-73. PubMed ID: 19477024
[TBL] [Abstract][Full Text] [Related]
37. New usage paradigms in antibody therapy: safety of the new agents.
Pescovitz MD
Transplant Proc; 1999; 31(1-2):1201-2. PubMed ID: 10083537
[No Abstract] [Full Text] [Related]
38. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications.
Chatenoud L
Curr Opin Immunol; 2005 Dec; 17(6):632-7. PubMed ID: 16214320
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic use of the monoclonal antibody Orthoclone OKT3.
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-58. PubMed ID: 3105133
[No Abstract] [Full Text] [Related]
40. Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo.
Carpenter PA; Tso JY; Press OW; Yu X; Anasetti C
Transplant Proc; 2000 Nov; 32(7):1545-6. PubMed ID: 11119827
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
